Visok nivo interleukina-10 u serumu nakon terapije karakterističan je za bolesnike sa karcinomom prostate koji imaju visok Gleason gradus, veliki volumen tumora i prisutnu peritumorsku infiltraciju
Sažetak
Background/Aim. Skorašnji podaci ukazuju na značaj pojedinih citokina u pojavi i razvoju karcinoma prostate (KP), kao i na njihovu udruženost sa patohistološkim i/ili kliničkim karakteristikama KP. Cilj studije bio je da se ispita udruženost koncentracije interleukina-10 (IL-10) sa patohistološkim i kliničkim karakteristikama bolesti kod bolesnika sa KP. Metode. Koncentracija IL-10 određivana je u uzorcima seruma, urina i prostate massage secret (pms) kod 88 bolesnika sa KP (inicijalno i posle terapije), 20 bolesnika sa benignom hiperplazijom prostate (BHP) i 15 zdravih osoba (kontrolna grupa). Rezultati. U poređenju sa bolesnicima sa BPH i kontrolnom grupom, bolesnici sa KP imali su najveće serumske vrednosti IL-10. Interesantno, bolesnici sa BHP imali su najviše koncentracije IL-10 u urinu i uzorcima pms. Takođe, bolesnici sa G3 gradusom i najvećim Gleason skorom (4 + 4) imali su najveće serumske vrednosti IL-10. Bolesnici sa KP bez ikakvog patohistološkog znaka invazije tumora, u odnosu na bolesnike sa evidentnom invazijom tumorskih ćelija, imali su značajno povećane serumske vrednosti IL-10, kako pre, tako i posle terapije. Terapija je indukovala različite profile IL-10 u uzorcima seruma i urina. Nakon terapije detektovali smo značajno povišenje serumskih vrednosti
IL-10 kod bolesnika sa nepovoljnim Gleason skorom (4 + 4), prisutnom infitracijom tumorskih ćelija u peritumorskom tkivu (limfnom, vaskularnom ili kombinovano) i u grupi bolesnika sa visokim volumenom tumora. Zaključak. Bolesnici sa KP bez patohistoloških znakova invazije tumora pre terapije imaju značajno povišene vrednosti serumskog IL-10 u odnosu na grupu bolesnika sa dokazanom invazijom. U našem istraživanju postoji jasna disocijacija vrednosti IL-10 u uzorcima seruma, urina i pms pojedinačnog bolesnika. Posle terapije, visoka koncentracija IL-10 u serumu prisutna je samo kod bolesnika sa visokim Gleason skorom, prisutnom infiltracijom peritumorskog tkiva i visokim volumenom tumora.
Reference
Patel AR, Klein EA. Risk factors for prostate cancer. Nat Clin Pract Urol 2009; 6(2): 87–95.
Ricote M, Garcia-Tuñon F, Bethencourt, M. Interleukin-1 (IL-1alpha and IL-1beta) and its receptors (IL-1RI, IL-1RII, and IL-1Ra) in prostate carcinoma. Cancer 2004; 100: 1388‒96.
Tazaki E, Shimizu N, Tanaka R, Yoshizumi M, Kamma H, Imoto S, et al. Serum cytokine profiles in patients with prostate car-cinoma. Exp Ther Med 2011; 2(5): 887‒91.
Lin WW, Karin M. A cytokine-mediated link between innate immunity, inflammation, and cancer. J Clin Invest 2007; 117(5): 1175–83.
de Visser KE, Eichten A, Coussens LM. Paradoxical roles of the immune system during cancer development. Nat Rev Cancer 2006; 6(1): 24‒37.
Swann JB, Smyth MJ. Immune surveillance of tumors. J Clin Invest 2007; 117(5): 1137‒46.
Tindall EA, Severi G, Hoang HN, Ma CS, Fernandez P, Southey MC, et al. Australian Prostate Cancer BioResource. Compre-hensive analysis of the cytokine-rich chromosome 5q31.1 re-gion suggests a role for IL-4 gene variants in prostate cancer risk. Carcinogenesis 2010; 31(10): 1748‒54.
Xu H, Hu MB, Bai PD, Zhu WH, Liu SH, Hou JY, et al. Proin-flammatory cytokines in prostate cancer development and progression promoted by high-fat diet. Biomed Res Int 2015; 2015: 249741.
Christensen E, Pintilie M, Evans KR, Lenarduzzi M, Ménard C, Catton CN, et al. Longitudinal cytokine expression during IMRT for prostate cancer and acute treatment toxicity. Clin Cancer Res 2009; 15(17): 5576‒83.
Mahon KL, Lin HM, Castillo L, Lee BY, Lee-Ng M, Chatfield MD, et al. Cytokine profiling of docetaxel-resistant castra-tion-resistant prostate cancer. Br J Cancer 2015; 112(8): 1340‒8.
Fujita K, Ewing CM, Isaacs WB, Pavlovich CP. Immunomodula-tory IL-18 binding protein is produced by prostate cancer cells and its levels in urine and serum correlate with tumor status. Int J Cancer 2011; 129(2): 424‒32.
Cerović S, Brajušković G, Vukotić V. Premalignant lesions and prostate cancer. Belgrade: IP Beograd d.o.o; 2009. (Serbian)
Brierley J, Gospodarowicz MK, Wittekind C. 8th Edition of the UICC TNM classification of Malignant Tumors [published 2016 December 1]. Available from: https://www.uicc.org/news/8th-edition-uicc-tnm-classification-malignant-tumors-published
Vignozzi L, Cellai I, Santi R, Lombardelli L, Morelli A, Comeglio P et al. Antiinflammatory effect of androgen receptor activa-tion in human benign prostatic hyperplasia cells. J Endocrinol 2012; 214(1): 31‒43.
Turner DM, Williams DM, Sankaran D, Lazarus M, Sinnott PJ, Hutchinson IV. An investigation of polymorphism in the inter-leukin-10 gene promoter. Eur J Immunogenet 1997; 24(1): 1‒8.
Eskdale J, Gallagher G, Verweij CL, Keijsers V, Westendorp RG, Huizinga TW. Interleukin 10 secretion in relation to human IL-10 locus haplotypes. Proc Natl Acad Sci U S A 1998; 95(16): 9465‒70.
Michaud DS, Daugherty SE, Berndt SI, Platz EA, Yeager M, Crawford ED, et al. Genetic polymorphisms of interleukin-1B (IL-1B), IL-6, IL-8, and IL-10 and risk of prostate cancer. Cancer Res 2006; 66(8): 4525‒30.
Eder T, Mayer R, Langsenlehner U, Renner W, Krippl P, Wascher TC, et al. Interleukin-10 [ATA] promoter haplotype and pros-tate cancer risk: A population-based study. Eur J Cancer 2007; 43(3): 472–5.
Zou YF, Wang F, Feng XL, Tian YH, Tao JH, Pan FM, Huang F. Lack of association of IL-10 gene polymorphisms with prostate cancer: evidence from 11,581 subjects. Eur J Cancer 2011; 47(7): 1072‒9.
Shao N, Xu B, Mi YY, Hua LX. IL-10 polymorphisms and prostate cancer risk: a meta-analysis. Prostate Cancer Prostatic Dis 2011; 14(2): 129‒35.
Kwon EM, Salinas CA, Kolb S, Fu R, Feng Z, Stanford JL, et al. Genetic polymorphisms in inflammation pathway genes and prostate cancer risk. Cancer Epidemiol Biomarkers Prev 2011; 20(5): 923‒33.
Kazma R, Mefford JA, Cheng I, Plummer SJ, Levin AM, Rybicki BA, et al. Association of the Innate Immunity and Inflamma-tion Pathway with Advanced Prostate Cancer Risk. PLoS ONE 2012; 7(12): e51680.
Yu Z, Liu Q, Huang C, Wu M, Li G. The interleukin 10 -819C/T polymorphism and cancer risk: a HuGE review and meta-analysis of 73 studies including 15,942 cases and 22,336 controls. OMICS 2013; 17(4): 200‒14.
Winchester DA, Gurel B, Till C, Goodman PJ, Tangen CM, Santel-la RM, et al. Key genes involved in the immune response are generally not associated with intraprostatic inflammation in men without a prostate cancer diagnosis: Results from the prostate cancer prevention trial. Prostate 2016; 76(6): 565‒74.
McCarron SL, Edwards S, Evans PR, Gibbs R, Dearnaley DP, Dowe A, et al. Influence of cytokine gene polymorphisms on the development of prostate cancer. Cancer Res 2002; 62(12): 3369–72.
Faupel-Badger JM, Kidd LC, Albanes D, Virtamo J, Woodson K, Tangrea JA. Association of IL-10 polymorphisms with prostate cancer risk and grade of disease. Cancer Causes Control 2008, 19(2): 119-24.
Zabaleta J, Lin HY, Sierra RA, Hall MC, Clark PE, Sartor OA, et al. Interactions of cytokine gene polymorphisms in prostate cancer risk. Carcinogenesis 2008; 29(3): 573–8.
Zabaleta J, Su LJ, Lin HY, Sierra RA, Hall MC, Sartor AO, et al. Cytokine genetic polymorphisms and prostate cancer ag-gressiveness. Carcinogenesis 2009; 30(8): 1358‒62.
Wang MH, Helzlsouer KJ, Smith MW, Hoffman-Bolton JA, Clipp SL, Grinberg V, et al. Association of IL10 and other immune response- and obesity-related genes with prostate cancer in CLUE II. Prostate 2009; 69(8): 874‒85.
Kesarwani P, Ahirwar DK, Mandhani A, Singh AN, Dalela D, Srivastava AN, et al. IL-10 -1082 G>A: a risk for prostate cancer but may be protective against progression of prostate cancer in North Indian cohort. World J Urol 2009; 27(3): 389‒96.
Dluzniewski PJ, Wang MH, Zheng SL, De Marzo AM, Drake CG, Fedor HL, et al. Variation in IL10 and other genes in-volved in the immune response and in oxidation and prostate cancer recurrence. Cancer Epidemiol Biomarkers Prev 2012; 21(10): 1774‒82.
Ianni M, Porcellini E, Carbone I, Potenzoni M, Pieri AM, Pas-tizzaro CD, et al. Genetic factors regulating inflammation and DNA methylation associated with prostate cancer. Prostate Cancer Prostatic Dis 2013; 16(1): 56‒61.
Eeles R, Goh C, Castro E, Bancroft E, Guy M, Al Olama AA, et al. The genetic epidemiology of prostate cancer and its clinical implications. Nat Rev Urol 2014; 11(1): 18‒31.
Shi X, Xie X, Xun X, Jia Y, Li S. Associations of IL-10 genet-ic polymorphisms with the risk of urologic cancer: a meta-analysis based on 18,415 subjects. Springerplus 2016; 5(1): 2034.
Chen H, Tang J, Shen N, Ren K. Interleukin 10 gene rs1800896 polymorphism is associated with the risk of prostate cancer. Oncotarget 2017; 8(39): 66204‒14.
Men T, Yu C, Wang D, Liu F, Li J, Qi X, et al. The impact of interleukin-10 (IL-10) gene 4 polymorphisms on peripheral blood IL-10 variation and prostate cancer risk based on pub-lished studies. Oncotarget 2017; 8(28): 45994‒6005.
Horvat V, Mandić S, Marczi S, Mrčela M, Galić J. Association of IL-1β and IL-10 Polymorphisms with Prostate Cancer Risk and Grade of Disease in Eastern Croatian Population. Coll Antropol 2015; 39(2): 393‒400.
Stearns ME, Rhim J, Wang M. Interleukin 10 (IL-10) inhibition of primary human prostate cell-induced angiogenesis: IL-10 stimulation of tissue inhibitor of metalloproteinase-1 and in-hibition of matrix metalloproteinase (MMP)-2/MMP-9 secre-tion. Clin Cancer Res 1999; 5(1): 189‒96.
Liu J, Song B, Bai X, Liu W, Li Z, Wang J, et al. Association of genetic polymorphisms in the interleukin-10 promoter with risk of prostate cancer in Chinese. BMC Cancer 2010; 10: 456.
Cardillo MR, Ippoliti F. IL-6, IL-10 and HSP-90 expression in tissue microarrays from human prostate cancer assessed by computer-assisted image analysis. Anticancer Res 2006; 26(5A): 3409‒16.
Hu W, Qian Y, Yu F, Liu W, Wu Y, Fang X, Hao W. Alterna-tively activated macrophages are associated with metastasis and poor prognosis in prostate adenocarcinoma. Oncol Lett 2015; 10(3): 1390‒6.
Itakura E, Huang RR, Wen DR, Paul E, Wünsch PH, Cochran AJ. IL-10 expression by primary tumor cells correlates with melanoma progression from radial to vertical growth phase and development of metastatic competence. Mod Pathol 2011; 24(6): 801‒9.
Zhen Z, Guo X, Liao R, Yang K, Ye L, You Z. Involvement of IL-10 and TGF-β in HLA-E-mediated neuroblastoma migra-tion and invasion. Oncotarget 2016; 7(28): 44340‒9.
Li L, Sun P, Zhang C, Li Z, Zhou W. MiR-98 suppresses the ef-fects of tumor-associated macrophages on promoting migra-tion and invasion of hepatocellular carcinoma cells by regulat-ing IL-10. Biochimie 2018; 150: 23‒30.
Wang R, Lu M, Zhang J, Chen S, Luo X, Qin Y, Chen H. In-creased IL-10 mRNA expression in tumor-associated macro-phage correlated with late stage of lung cancer. J Exp Clin Cancer Res 2011; 30: 62.
Ahmad N, Ammar A, Storr SJ, Green AR, Rakha E, Ellis IO, et al. IL-6 and IL-10 are associated with good prognosis in early stage invasive breast cancer patients. Cancer Immunol Immu-nother 2018; 67(4): 537‒49.
Stearns ME, Wang M. Antimestatic and antitumor activities of interleukin 10 in transfected human prostate PC-3 ML clones: Orthotopic growth in severe combined immunodeficient mice. Clin Cancer Res 1998; 4(9): 2257‒63.
Yu D, Zhong Y, Li X, Li Y, Li X, Cao J, et al. ILs-3, 6 and 11 increase, but ILs-10 and 24 decrease stemness of human pros-tate cancer cells in vitro. Oncotarget 2015; 6(40): 42687‒703.
Dwivedi S, Goel A, Natu SM, Mandhani A, Khattri S, Pant KK. Diagnostic and prognostic significance of prostate specific an-tigen and serum interleukin 18 and 10 in patients with locally advanced prostate cancer: a prospective study. Asian Pac J Cancer Prev 2011; 12(7): 1843‒8.